Phase Genomics: David Shoultz
David Shoultz has been appointed as the first chief business officer of Phase Genomics. He comes to the Seattle-based firm from Monod Bio, a spinout from the Institute for Protein Design that he cofounded and where he served as chief operating officer. Previously, he was a member of the global health product development team at the Bill & Melinda Gates Foundation, directed the global drug development program at PATH, and held scientific leadership positions at Neoleukin Therapeutics and PPD (now part of Thermo Fisher Scientific).